Verastem is a biopharmaceutical company developing cancer treatments for the United States market. The company's main drug candidates include Avutometinib, an oral medication designed to inhibit RAF and MEK proteins involved in cancer cell growth, and Defactinib, an oral inhibitor targeting FAK and related enzymes in solid tumors. The company is conducting multiple clinical trials testing these drugs individually and in combination for conditions such as ovarian cancer and KRAS-mutant cancers, with partnerships that include licensing agreements with Chugai Pharmaceutical and Pfizer, as well as collaboration agreements with Amgen and GenFleet Therapeutics.

entry readiness 0 · NOT READY · exit proximity 65

Value area 3.43–8.07 · 5% of 120d volume overhead · clean runway